Chagas Disease/Leishmaniasis
| Development of the Neglected Tropical Diseases Drug Discovery Research Database
|
Astellas Pharma Inc. has been working with the Institute of Tropical Medicine, Nagasaki University, in collaboration with the National Institute of Advanced Industrial Science and Technology (AIST), the High Energy Accelerator Research Organization (KEK), and the London School of Hygiene and Tropical Medicine (LSHTM), to develop a new drug discovery database for Chagas disease. Astellas is providing advisory advice on the "Exploratory Research to Discover Target Molecules for the Development of New Therapeutic Agents for Chagas Disease," which is being conducted in collaboration with the National Institute of Advanced Industrial Science and Technology (AIST), the High Energy Accelerator Research Institute (KEK) and the London School of Hygiene and Tropical Medicine (LSHTM).
From April 2016 to September 2017, Astellas conducted joint research with AIST on new therapeutic agents for Chagas disease. In this joint research, the technological basis for finding molecules that are essential for the parasite's survival was developed using genome editing technology, enabling the selection of molecules with high drug discovery potential. The results of this research are being used in "Exploratory Research to Discover Target Molecules for the Development of New Therapeutics for Chagas Disease. |
|---|---|
| Screening and Hit-to-Lead Program for the Control of Infectious Diseases in Developing Countries (GHIT Fund Program) | Eisai is participating in the GHIT Fund program for the discovery of drug candidates for malaria, leishmaniasis, and Chagas disease. |
| Screening and Hit-to-Lead Program for the Control of Infectious Diseases in Developing Countries (GHIT Fund Program) | Daiichi Sankyo is participating in the GHIT Fund's screening program for NTDs (leishmaniasis and Chagas disease) using its own library (small molecules and natural products). Furthermore, Astellas is conducting joint research to optimize lead compounds for Chagas disease based on promising compounds discovered from the screening program. |
| Screening and Hit-to-Lead Program for the Control of Infectious Diseases in Developing Countries (GHIT Fund Program) | Astellas Pharma Inc. is participating in the GHIT Fund's screening program to discover candidates for tuberculosis and malaria, and is providing its compound library. Astellas Pharma Inc. is also participating in the GHIT Fund's Hit-to-Lead program for the discovery of lead compounds for NTDs (leishmaniasis and Chagas disease), and is providing its compound library. |
| Screening and Hit-to-Lead Program for the Control of Infectious Diseases in Developing Countries (GHIT Fund Program) | Mitsubishi Tanabe Pharma Corporation is participating in the GHIT Fund's Hit-to-Lead program for the discovery of lead compounds for malaria, leishmaniasis, and Chagas disease, and is providing its own compound library. |